1,423 results on '"Bergh, Jonas"'
Search Results
2. The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trial
3. Systematic review and feasibility study on pre-analytical factors and genomic analyses on archival formalin-fixed paraffin-embedded breast cancer tissue
4. Five-year follow-up of the OptiTrain trial on concurrent resistance and high-intensity interval training during chemotherapy for patients with breast cancer
5. Longitudinal molecular profiling elucidates immunometabolism dynamics in breast cancer
6. 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)
7. Current status of contemporary diagnostic radiotracers in the management of breast cancer: first steps toward theranostic applications
8. Adherence to endocrine therapy in early breast cancer in relation to Cytochrome P450 2D6 genotype: a comparison between pharmacy dispensation data and medical records
9. Gonadotropin Releasing Hormone agonist (GnRHa) during chemotherapy and post-cancer childbirths – a Nationwide population-based cohort study of 24,922 women diagnosed with cancer in Sweden
10. Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials
11. Risk-adjusted benchmarking of long-term overall survival in patients with HER2-positive early-stage Breast cancer: A Swedish retrospective cohort study
12. Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials
13. Women with short survival after diagnosis of metastatic breast cancer: a population-based registry study
14. Estimating benefit from dose dense adjuvant chemotherapy for early breast cancer in the PANTHER randomized phase 3 trial.
15. The value of anticancer drugs — a regulatory view
16. The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology
17. Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials
18. Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial.
19. Human Epidermal Growth Factor Receptor 2 (HER2) PET Imaging of HER2-Low Breast Cancer with [68Ga]Ga-ABY-025: Results from a Pilot Study.
20. MNK2 governs the macrophage antiinflammatory phenotype
21. Impact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients
22. Human Epidermal Growth Factor Receptor 2 (HER2) PET Imaging of HER2-Low Breast Cancer with [68Ga]Ga-ABY-025: Results from a Pilot Study
23. Carl Blomqvist, Nordic network builder in oncology (1951–2023) †
24. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
25. Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials
26. A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy
27. Unveiling the Power of Model-Agnostic Multiscale Analysis for Enhancing Artificial Intelligence Models in Breast Cancer Histopathology Images
28. Breast cancer during pregnancy—The oncologist's point of view.
29. PD-1 protein and gene expression as prognostic factors in early breast cancer
30. European Medicines Agency extension of indication to include the combination immunotherapy cancer drug treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) for adults with intermediate/poor-risk advanced renal cell carcinoma
31. Combinations in the first-line treatment of patients with advanced/metastatic renal cell cancer: regulatory aspects
32. Gonadotropin Releasing Hormone agonist (GnRHa) during chemotherapy and post-cancer childbirths – a Nationwide population-based cohort study of 24,922 women diagnosed with cancer in Sweden
33. ProFertil study protocol for the investigation of gonadotropin-releasing hormone agonists (GnRHa) during chemotherapy aiming at fertility protection of young women and teenagers with cancer in Sweden—a phase III randomised double-blinded placebo-controlled study
34. Breast cancer during pregnancy—The oncologist's point of view
35. Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study
36. Evidence-based prediction and prevention of cardiovascular morbidity in adults treated for cancer
37. A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
38. CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment
39. A pan-cancer analysis of the frequency of DNA alterations across cell cycle activity levels
40. Chemotherapy use near the end-of-life in patients with metastatic breast cancer
41. Caring for patients with cancer in the COVID-19 era
42. European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy
43. Author Correction: The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology
44. Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer
45. Microglia Induce PDGFRB Expression in Glioma Cells to Enhance Their Migratory Capacity
46. An immunosuppressive macrophage profile attenuates the prognostic impact of CD20-positive B cells in human soft tissue sarcoma
47. High-intensity exercise during chemotherapy induces beneficial effects 12 months into breast cancer survivorship
48. Prognosis in patients diagnosed with loco-regional failure of breast cancer: 34 years longitudinal data from the Stockholm–Gotland cancer registry
49. Notch signaling promotes a HIF2α-driven hypoxic response in multiple tumor cell types
50. RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.